Mr. Nolan brings to our Board 35 years of experience in the life sciences industry as a public company executive, operator and serial entrepreneur. His diverse functional expertise includes commercial operations, global marketing, and corporate and business development. Mr. Nolan previously served as CEO of AveXis (NYSE: AVXS), which he grew from four employees to a fully integrated global public company with research, clinical, regulatory, manufacturing and commercial operations that was ultimately sold to Novartis for $8.7 billion.

• Taysha Gene Therapies, Inc. (NASDAQ: TSHA)
  • Chief Executive Officer (since 2022)
  • Chairman of the Board (since 2020)
• President, Nolan Capital, LLC, an investment fund (since 2019)
• President and Chief Executive Officer, AveXis, Inc. (formerly NASDAQ: AVXS), a gene therapy company (2015-2018)
• Chief Business Officer, InterMune, Inc. (formerly NASDAQ: ITMN), a biopharmaceutical company (2013-2015)
• Chief Commercial Officer, Reata Pharmaceuticals, Inc. (NASDAQ: RETA), a pharmaceuticals company (2011-2012)
• Chief Commercial Officer and President, Lundbeck, Inc., a U.S. affiliate of H. Lundbeck A/S, a Danish pharmaceuticals company (2009-2010)

• Chairman of the Board, Jaguar Gene Therapy, LLC
• Chairman of the Board, Affinia Therapeutics Inc.
• Chairman of the Board, Encoded Therapeutics, Inc.
• Advisory Board Member, Goldman Sachs Life Sciences Fund

• Taysha Gene Therapies, Inc., Chairman of the Board (NASDAQ: TSHA) (since 2020)

• Neoleukin Therapeutics (now Neurogene, Inc.) (NASDAQ: NLTX) (2019-2020)
• Aquinox Pharmaceuticals, Inc. (formerly NASDAQ: AQXP) (2015-2019)